Skip to main content
Premium Trial:

Request an Annual Quote

Rosetta Genomics, MD Anderson to Collborate on Lung Cancer Dx

NEW YORK (GenomeWeb News) – Rosetta Genomics said today that it will collaborate with researchers at the MD Anderson Cancer Center and the Kleberg Center for Molecular Markers to develop a microRNA-based test to predict risk of disease recurrence in lung cancer patients who have undergone curative resection.
 
The partners said patients with high risk of recurrence may benefit from adjuvant therapy after surgical resection, but low-risk patients may be exposed to unnecessary toxicities.
They hope to develop a test that will enable physicians to distinguish between patients with high risk and low risk of recurrence, which would help them optimize treatment regimens.
 
“By leveraging microRNAs’ unique sensitivity as biomarkers, we have an opportunity to develop a novel test that will assist clinicians and patients to better manage this type of cancer,” Ignacio Wistuba, associate professor in the department of pathology at MD Anderson Cancer, said in a statement.
 
The Kleberg Center for Molecular Markers is part of MD Anderson.

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.